Home Biotechnology Merck & Co., Inc. (MSD)
M

Merck & Co., Inc. (MSD)

Profile managed by Bizz Id
United States

Description

MSD (Merck & Co., Inc., Rahway, New Jersey) is a research-focused biopharmaceutical company developing medicines and vaccines for people and animals. Its animal health business operates as MSD Animal Health. Not to be confused with Merck KGaA (Darmstadt).

Products

18 products
Bezlotoxumab

Brand: Zinplava. Injection, for intravenous use.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Bezlotoxumab: see suppliers →

Clesrovimab

Brand: Enflonsia. Injection, for intramuscular use.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Clesrovimab: see suppliers →

Gocatamig

MK-6070. Multi-specific antibody; TriTAC targeting DLL3. Small cell lung cancer. Phase 2. With Daiichi Sankyo.

Under development

Finished product (FDF)

Verified on 2026-10-21

Gocatamig: see suppliers →

Ifinatamab deruxtecan

MK-2400. ADC: anti-B7-H3 IgG1 linked to a topoisomerase I inhibitor. Previously treated extensive-stage SCLC under review in the US; Phase 3 in esophageal and prostate cancer. With Daiichi Sankyo.

Solicitud presentada: EE. UU.

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ifinatamab deruxtecan: see suppliers →

MK-1406 (neuraminidase inhibitor-Fc)

Therapeutic protein/conjugate; neuraminidase inhibitor linked to an Fc fragment. Influenza. Phase 3.

Under development

Finished product (FDF)

Verified on 2026-10-21

MK-2214 (anti-tau)

High-affinity anti-tau monoclonal antibody. Alzheimer's disease. Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

MK-3120 (Nectin-4 ADC)

ADC; Nectin-4 antibody with topoisomerase I payload. Bladder/prostate cancer. Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

MK-8690 (anti-CD30L)

Fully human anti-CD30L monoclonal antibody. Ulcerative colitis. Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

MK-8748 (Tie2/VEGF)

Multi-specific antibody; bispecific that activates Tie2 and inhibits VEGF. Neovascular AMD. Phase 2/3.

Under development

Finished product (FDF)

Verified on 2026-10-21

Patritumab deruxtecan

MK-1022. ADC; anti-HER3 linked to topoisomerase I inhibitor. Breast cancer in Phase 3; other solid tumors in Phase 2. With Daiichi Sankyo.

Under development

Finished product (FDF)

Verified on 2026-10-21

Patritumab deruxtecan: see suppliers →

Pembrolizumab

Brand: Keytruda. Anti-PD-1 monoclonal antibody; intravenous injection. New indications under review in EU/Japan (muscle-invasive bladder, high-risk endometrial, platinum-resistant ovarian cancer); Phase 3 in small cell lung cancer.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Pembrolizumab: see suppliers →

Pembrolizumab (SC)

Brand: Keytruda Qlex. Pembrolizumab and berahyaluronidase alfa; subcutaneous injection. Hematological malignancies in Phase 2.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Pembrolizumab: see suppliers →

Raludotatug deruxtecan

MK-5909. ADC; anti-CDH6 linked to topoisomerase I inhibitor. Ovarian cancer in Phase 3; cervical, endometrial, gastric and lung cancer in Phase 2. With Daiichi Sankyo.

Under development

Finished product (FDF)

Verified on 2026-10-21

Raludotatug deruxtecan: see suppliers →

Remigromig

MK-3000. Tri-specific antibody, Wnt pathway agonist. Diabetic macular edema. Phase 3.

Under development

Finished product (FDF)

Verified on 2026-10-21

Remigromig: see suppliers →

Sacituzumab tirumotecan

MK-2870. ADC; anti-TROP2 linked to belotecan-derived payload. Bladder, breast, cervical, endometrial, gastric, NSCLC and ovarian cancer in Phase 3. With Sichuan Kelun-Biotech.

Under development

Finished product (FDF)

Verified on 2026-10-21

Sacituzumab tirumotecan: see suppliers →

Sotatercept

Brand: Winrevair. Therapeutic protein, activin signaling inhibitor; subcutaneous injection. Pulmonary arterial hypertension (HYPERION) under review in the US; PH due to left heart disease in Phase 2.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Sotatercept: see suppliers →

Tulisokibart

MK-7240. Anti-TL1A monoclonal antibody. Crohn's disease and ulcerative colitis in Phase 3; axial spondyloarthritis, hidradenitis suppurativa, psoriatic arthritis, rheumatoid arthritis and systemic sclerosis in Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

Tulisokibart: see suppliers →

Zilovertamab vedotin

MK-2140. ADC; anti-ROR1 linked to MMAE. Hematological malignancies. Phase 3.

Under development

Finished product (FDF)

Verified on 2026-10-21

Zilovertamab vedotin: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free